Deep vein thrombosis: pathogenesis, diagnosis, and medical management.
暂无分享,去创建一个
Rahmi Oklu | H. Albadawi | R. Oklu | F. Shamoun | S. Naidu | Patrick T. Hangge | Hassan Albadawi | Jonathan Stone | Patrick Hangge | Alex Wallace | Fadi Shamoun | M Grace Knuttien | Sailendra Naidu | A. Wallace | J. Stone | M. G. Knuttien | M. Grace Knuttien
[1] E. Husni. Pathogenesis of venous thrombosis. , 1971, JAMA.
[2] S. Goldhaber,et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.
[3] G. Raskob,et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.
[4] Bruce L Davidson,et al. Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.
[5] M. Armon,et al. Thrombolysis for acute deep vein thrombosis , 1996, The Cochrane database of systematic reviews.
[6] S. Wicky,et al. Efficacy of Lower-Extremity Venous Thrombolysis in the Setting of Congenital Absence or Atresia of the Inferior Vena Cava , 2012, CardioVascular and Interventional Radiology.
[7] F. Rybicki,et al. ACR Appropriateness Criteria(®) on suspected lower extremity deep vein thrombosis. , 2011, Journal of the American College of Radiology : JACR.
[8] T. Ortel,et al. Venous thromboembolism: a public health concern. , 2010, American journal of preventive medicine.
[9] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[10] S. Wicky,et al. Catheter-Directed Thrombolysis of Deep Venous Thrombosis , 2013, Seminars in Thrombosis & Hemostasis.
[11] G. Stansby,et al. The management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE Guideline CG144. , 2012, Acute medicine.
[12] Adnan Memić,et al. Pathogenesis of Thromboembolism and Endovascular Management , 2017, Thrombosis.
[13] C. Esmon. Basic mechanisms and pathogenesis of venous thrombosis. , 2009, Blood reviews.
[14] A. Nicolaides,et al. The origin of deep vein thrombosis: a venographic study. , 1971, The British journal of radiology.
[15] R. Bertina. Elevated Clotting Factor Levels and Venous Thrombosis , 2003, Pathophysiology of Haemostasis and Thrombosis.
[16] W M O'Fallon,et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. , 1998, Archives of internal medicine.
[17] T. Baglin,et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[18] S. Yale,et al. Virchow’s Contribution to the Understanding of Thrombosis and Cellular Biology , 2010, Clinical Medicine & Research.
[19] L. Tamariz,et al. Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. , 2003, The American journal of medicine.
[20] R. White,et al. The epidemiology of venous thromboembolism. , 2003, Circulation.
[21] R. Gans,et al. Oral rivaroxaban for symptomatic venous thromboembolism. , 2011, The New England journal of medicine.
[22] F. Sampson,et al. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis , 2006, European Radiology.
[23] P. Cancilla,et al. Use of endothelium cultured on microcarriers as a model for the microcirculation. , 1982, Laboratory investigation; a journal of technical methods and pathology.
[24] Steve Goodacre,et al. Bmc Medical Imaging Systematic Review and Meta-analysis of the Diagnostic Accuracy of Ultrasonography for Deep Vein Thrombosis , 2005 .
[25] L. Sandvik,et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial , 2012, The Lancet.
[26] Y. Loke,et al. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta‐analysis and adjusted indirect comparison , 2014, British journal of clinical pharmacology.
[27] J. Julian,et al. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. , 1998, Annals of internal medicine.
[28] G. Raskob,et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.
[29] S. Wicky,et al. Catheter-Directed Thrombolysis of Arterial Thrombosis , 2013, Seminars in Thrombosis & Hemostasis.
[30] A. Dans,et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[31] C. Kearon,et al. Natural History of Venous Thromboembolism , 2003, Circulation.
[32] J. McLachlin,et al. Precipitating factors in venous thrombosis. , 1954, Surgery, gynecology & obstetrics.
[33] Gordon H. Guyatt,et al. Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis , 2011 .
[34] Jonathan Dreyer,et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. , 2003, The New England journal of medicine.
[35] C. Esmon,et al. Valves of the deep venous system: an overlooked risk factor. , 2007, Blood.
[36] F. Belloc,et al. Influence of hypoxia and hypoxia-reoxygenation on endothelial P-selectin expression. , 1996, Haemostasis.
[37] Giancarlo Agnelli,et al. Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.
[38] S. Goldhaber,et al. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis , 2014, Circulation.
[39] Adam Torbicki,et al. Management of venous thrombo-embolism: an update. , 2014, European heart journal.
[40] R. Lopes,et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism , 2016, Journal of Thrombosis and Thrombolysis.
[41] F. Rosendaal,et al. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use , 2003, Thrombosis and Haemostasis.
[42] I. Silver,et al. The PO2 in venous valve pockets: Its possible bearing on thrombogenesis , 1981, The British journal of surgery.
[43] E. Horváth-Puhó,et al. 30-Year Mortality After Venous Thromboembolism: A Population-Based Cohort Study , 2014, Circulation.
[45] S Sevitt,et al. The structure and growth of valve-pocket thrombi in femoral veins , 1974, Journal of clinical pathology.
[46] D. Lamping,et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. , 2008, Annals of internal medicine.
[47] F. Sampson,et al. Diagnostic value of CT for deep vein thrombosis: results of a systematic review and meta-analysis. , 2008, Clinical radiology.
[48] L. Rao,et al. Tissue factor as a tumor procoagulant , 1992, Cancer and Metastasis Reviews.
[49] K. Rabinov,et al. Roentgen diagnosis of venous thrombosis in the leg. , 1972, Archives of surgery.
[50] John A. Heit,et al. The epidemiology of venous thromboembolism , 2003, Journal of Thrombosis and Thrombolysis.
[51] M. C. Sheps,et al. Biologic assay of a thrombosis-inducing activity in human serum. , 1959, Journal of applied physiology.
[52] Chad J Zack,et al. Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosis. , 2014, JAMA internal medicine.
[53] Young Hwan Kim,et al. Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines , 2016, Vascular specialist international.
[54] Adrian V. Hernández,et al. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. , 2012, Archives of internal medicine.
[55] Jason C. Fish,et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[56] Wendy Lim,et al. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. , 2014, Blood.
[57] Susan Regan,et al. Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. , 2003, Archives of internal medicine.
[58] D. Wagner,et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. , 2003, Journal of vascular surgery.
[59] J. Ericsson,et al. Postmortem Intraosseous Phlebography as an Aid in Studies of Venous Thromboembolism , 1969, Angiology.
[60] M. Math,et al. Noninvasive Diagnosis of Deep Venous Thrombosis , 1998, Annals of Internal Medicine.
[61] M. Watkins,et al. Detection of extracellular genomic DNA scaffold in human thrombus: implications for the use of deoxyribonuclease enzymes in thrombolysis. , 2012, Journal of vascular and interventional radiology : JVIR.
[62] F. Rosendaal. Venous thrombosis: a multicausal disease , 1999, The Lancet.
[63] F. García-Bragado Dalmau. [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. , 2013, Revista clinica espanola.
[64] M. Watkins,et al. Reduced hind limb ischemia-reperfusion injury in Toll-like receptor-4 mutant mice is associated with decreased neutrophil extracellular traps. , 2013, Journal of vascular surgery.
[65] angesichts der Corona-Pandemie,et al. UPDATE , 1973, The Lancet.
[66] S. Doucette,et al. Does this patient have deep vein thrombosis? , 1998, JAMA.
[67] Janis Bormanis,et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management , 1997, The Lancet.
[68] S. Kahn,et al. Postthrombotic syndrome: a 2014 update , 2014, Current opinion in cardiology.
[69] N. Abraham,et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study , 2015, BMJ : British Medical Journal.